In response to the COVID-19 pandemic, the pharmaceutical industry has shifted from ‘doing digital’ toward ‘being digital’. But sustaining this new level of innovation and collaboration will require the industry to bake-in even further digitization, automation, and integration of quality controls across value chains. This includes accelerated health authority oversight, the remote patient monitoring of at-home clinical trials, and the streamlining of drug development and review processes.